Login to Your Account

Gryphon’s Blood Booster Product Nets Potential $155M Roche Deal

By Randall Osborne

Tuesday, March 26, 2002
A powerful vote of confidence in Gryphon Sciences Inc.’s chemically synthesized proteins came in the form of a deal worth up to $155 million with F. Hoffmann-La Roche Ltd. for a red blood cell booster that the latter will develop for chemotherapy and hemodialysis patients. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription